Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.33||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||26.39%||Sales Growth - Q/Q||-3.32%||P/E||-8.88|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-28.56%||ROE||99.49%||ROI||-38.89%|
|Current Ratio||4.46||Quick Ratio||4.08||Long Term Debt/Equity||1.49||Debt Ratio||-0.69|
|Gross Margin||63.04%||Operating Margin||-164.67%||Net Profit Margin||-103.96%||Dividend Payout Ratio|
|Cash From Financing Activities||54.3 M||Cash From Investing Activities||Cash From Operating Activities||-12.64 M||Gross Profit||10.31 M|
|Net Profit||-31.13 M||Operating Profit||-27.05 M||Total Assets||215.34 M||Total Current Assets||189.75 M|
|Total Current Liabilities||42.53 M||Total Debt||233.48 M||Total Liabilities||277.16 M||Total Revenue||15.93 M|
|High 52 week||22.98||Low 52 week||2.45||Last close||17.79||Last change||2.3%|
|RSI||37.69||Average true range||0.81||Beta||0.51||Volume||2.65 M|
|Simple moving average 20 days||-0.63%||Simple moving average 50 days||-5.2%||Simple moving average 200 days||16.52%|
|Performance Week||2.77%||Performance Month||0.74%||Performance Quart||0.74%||Performance Half||15.67%|
|Performance Year||455.94%||Performance Year-to-date||30.71%||Volatility daily||2.76%||Volatility weekly||6.17%|
|Volatility monthly||12.65%||Volatility yearly||43.83%||Relative Volume||527.59%||Average Volume||7.26 M|
|New High||New Low|
2019-06-21 13:39:19 | Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences
2019-06-19 20:11:34 | Hedge Funds Have Never Been This Bullish On Amarin Corporation plc AMRN
2019-06-18 07:00:00 | Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
2019-06-17 22:26:39 | Amarin Stock Poised for Even More Gains
2019-06-07 07:12:35 | Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association ADA Meeting
2019-06-04 14:10:11 | Amarin Corporation plc NASDAQ:AMRN: When Will It Breakeven?
2019-06-04 06:00:00 | Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-30 16:03:32 | 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR
2019-05-30 08:28:12 | Amarin Rises on Priority Review for Vascepa Label Expansion
2019-05-30 07:31:00 | 3 Top Mid-Cap Stocks to Buy Right Now
2019-05-29 23:44:21 | This Biotech Stock Rocketed Near A Buy Point On Speedy Drug Review
2019-05-29 16:32:00 | Why Cypress Semiconductor, Amarin, and Heico Jumped Today
2019-05-29 13:04:08 | Bulls shop at this discount retailer
2019-05-29 11:58:00 | Here's Why Amarin Soared Today
2019-05-24 13:20:06 | Options traders say it's hip to be Square
2019-05-23 07:31:00 | Label Expansion to Boost Revenue Growth for Amarin’s Vascepa
2019-05-22 11:10:02 | How Did Amarin’s Vascepa Perform in Fiscal 2019?
2019-05-22 09:40:02 | Comparing Revenue Growth Trends for AMRN and IOVA
2019-05-22 08:07:37 | What Are Analysts Recommending for AMRN and IOVA in May?
2019-05-06 10:16:01 | Why Did Amarin AMRN Stock Sink After Earnings? Analysts Explain
2019-05-02 14:18:14 | 5 Biotech Stocks With Near-Term Catalysts Ahead
2019-05-02 09:34:01 | Options Traders Expect Huge Moves in Amarin AMRN Stock
2019-05-02 08:33:00 | Why Amarin's Stock Sank on Strong First-Quarter Results
2019-05-01 15:00:00 | Here's What You Need to Know From Amarin's Q1 Earnings Update
2019-05-01 13:47:03 | Edited Transcript of AMRN earnings conference call or presentation 1-May-19 11:30am GMT
2019-05-01 11:54:49 | Amarin Corporation plc AMRN Q1 2019 Earnings Call Transcript
2019-05-01 08:53:12 | Amarin AMRN Beats Estimates for Earnings & Revenues in Q1
2019-05-01 05:10:34 | Amarin: 1Q Earnings Snapshot
2019-05-01 05:00:00 | Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations
2019-04-29 21:43:00 | 4 More Healthcare Earnings Reports to Watch This Week
2019-04-29 06:00:00 | New Drug Submission Filed for Vascepa® with Health Canada
2019-04-25 12:24:02 | What Kind Of Investor Owns Most Of Amarin Corporation plc NASDAQ:AMRN?
2019-04-24 13:32:56 | Were Hedge Funds Right About Flocking Into Amarin Corporation plc AMRN ?
2019-04-24 12:06:04 | What's in the Cards for Amarin AMRN This Earnings Season?
2019-04-24 06:00:00 | Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019
2019-04-23 11:03:00 | DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-22 21:55:00 | FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-22 15:00:00 | FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC
2019-04-22 11:17:43 | DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-04-22 09:58:00 | FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC